Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group

Andrea K. Ng; Joachim Yahalom; Jayant S. Goda; Louis S. Constine; Chelsea C. Pinnix; Chris R. Kelsey; Bradford Hoppe; Masahiko Oguchi; Chang Ok Suh; Andrew Wirth; Shunan Qi; Andrew Davies; Craig H. Moskowitz; Siddhartha Laskar; Yexiong Li; Peter M. Mauch; Lena Specht; Timothy Illidge

doi:10.1016/j.ijrobp.2017.12.005

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group

Andrea K. Ng, Joachim Yahalom, Jayant S. Goda, Louis S. Constine, Chelsea C. Pinnix, Chris R. Kelsey, Bradford Hoppe, Masahiko Oguchi, Chang Ok Suh, Andrew Wirth, Shunan Qi, Andrew Davies, Craig H. Moskowitz, Siddhartha Laskar, Yexiong Li, Peter M. Mauch, Lena Specht, Timothy Illidge

Department of Radiation Oncology

Research output: Contribution to journal › Review article › peer-review

52 Citations (Scopus)

Abstract

Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.

Original language	English
Pages (from-to)	652-669
Number of pages	18
Journal	International Journal of Radiation Oncology Biology Physics
Volume	100
Issue number	3
DOIs	https://doi.org/10.1016/j.ijrobp.2017.12.005
Publication status	Published - 2018 Mar 1

Bibliographical note

Funding Information:
Conflict of interest: Dr Davies reports grants, personal fees, and nonfinancial support from F. Hoffmann La-Roche; grants and personal fees from Celgene; grants, personal fees, and nonfinancial support from Gilead Pharma; grants, personal fees, and nonfinancial support from Takeda; personal fees and nonfinancial support from CTI; personal fees and nonfinancial support from Mundipharma; grants from GSK; grants from Janssen; grants and personal fees from Pfizer; grants and personal fees from Karyopharma; and grants from Acerta; outside the submitted work. Dr Specht reports personal fees and nonfinancial support from Takeda, personal fees from Merck, and grants from Varian, outside the submitted work.

Publisher Copyright:
© 2017 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijrobp.2017.12.005

Cite this

Ng, A. K., Yahalom, J., Goda, J. S., Constine, L. S., Pinnix, C. C., Kelsey, C. R., Hoppe, B., Oguchi, M., Suh, C. O., Wirth, A., Qi, S., Davies, A., Moskowitz, C. H., Laskar, S., Li, Y., Mauch, P. M., Specht, L., & Illidge, T. (2018). Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 100(3), 652-669. https://doi.org/10.1016/j.ijrobp.2017.12.005

@article{2b4fb016ecf540a0a978baeeb66bd4d6,

title = "Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group",

abstract = "Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.",

author = "Ng, {Andrea K.} and Joachim Yahalom and Goda, {Jayant S.} and Constine, {Louis S.} and Pinnix, {Chelsea C.} and Kelsey, {Chris R.} and Bradford Hoppe and Masahiko Oguchi and Suh, {Chang Ok} and Andrew Wirth and Shunan Qi and Andrew Davies and Moskowitz, {Craig H.} and Siddhartha Laskar and Yexiong Li and Mauch, {Peter M.} and Lena Specht and Timothy Illidge",

note = "Funding Information: Conflict of interest: Dr Davies reports grants, personal fees, and nonfinancial support from F. Hoffmann La-Roche; grants and personal fees from Celgene; grants, personal fees, and nonfinancial support from Gilead Pharma; grants, personal fees, and nonfinancial support from Takeda; personal fees and nonfinancial support from CTI; personal fees and nonfinancial support from Mundipharma; grants from GSK; grants from Janssen; grants and personal fees from Pfizer; grants and personal fees from Karyopharma; and grants from Acerta; outside the submitted work. Dr Specht reports personal fees and nonfinancial support from Takeda, personal fees from Merck, and grants from Varian, outside the submitted work. Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2018",

month = mar,

day = "1",

doi = "10.1016/j.ijrobp.2017.12.005",

language = "English",

volume = "100",

pages = "652--669",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "3",

}

Ng, AK, Yahalom, J, Goda, JS, Constine, LS, Pinnix, CC, Kelsey, CR, Hoppe, B, Oguchi, M, Suh, CO, Wirth, A, Qi, S, Davies, A, Moskowitz, CH, Laskar, S, Li, Y, Mauch, PM, Specht, L & Illidge, T 2018, 'Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group', International Journal of Radiation Oncology Biology Physics, vol. 100, no. 3, pp. 652-669. https://doi.org/10.1016/j.ijrobp.2017.12.005

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. / Ng, Andrea K.; Yahalom, Joachim; Goda, Jayant S. et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 100, No. 3, 01.03.2018, p. 652-669.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

T2 - Guidelines from the International Lymphoma Radiation Oncology Group

AU - Ng, Andrea K.

AU - Yahalom, Joachim

AU - Goda, Jayant S.

AU - Constine, Louis S.

AU - Pinnix, Chelsea C.

AU - Kelsey, Chris R.

AU - Hoppe, Bradford

AU - Oguchi, Masahiko

AU - Suh, Chang Ok

AU - Wirth, Andrew

AU - Qi, Shunan

AU - Davies, Andrew

AU - Moskowitz, Craig H.

AU - Laskar, Siddhartha

AU - Li, Yexiong

AU - Mauch, Peter M.

AU - Specht, Lena

AU - Illidge, Timothy

N1 - Funding Information: Conflict of interest: Dr Davies reports grants, personal fees, and nonfinancial support from F. Hoffmann La-Roche; grants and personal fees from Celgene; grants, personal fees, and nonfinancial support from Gilead Pharma; grants, personal fees, and nonfinancial support from Takeda; personal fees and nonfinancial support from CTI; personal fees and nonfinancial support from Mundipharma; grants from GSK; grants from Janssen; grants and personal fees from Pfizer; grants and personal fees from Karyopharma; and grants from Acerta; outside the submitted work. Dr Specht reports personal fees and nonfinancial support from Takeda, personal fees from Merck, and grants from Varian, outside the submitted work. Publisher Copyright: © 2017 Elsevier Inc.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.

AB - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.

UR - http://www.scopus.com/inward/record.url?scp=85044650018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044650018&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2017.12.005

DO - 10.1016/j.ijrobp.2017.12.005

M3 - Review article

C2 - 29413279

AN - SCOPUS:85044650018

SN - 0360-3016

VL - 100

SP - 652

EP - 669

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 3

ER -

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this